Lemborexant Side Effects
Lemborexant is generally well-tolerated with somnolence being the most common side effect, occurring in approximately 7% of patients compared to 3% with placebo, though serious adverse events are rare and not more frequent than placebo.
Common Side Effects
The most frequently reported adverse events with lemborexant include:
Somnolence (daytime sleepiness): This is the primary side effect, occurring in a dose-dependent manner. At approved doses (5-10 mg), somnolence rates are approximately 7% versus 3% for placebo 1. This is typically mild to moderate in severity and rarely causes treatment discontinuation 2, 3.
Headache: Commonly reported across clinical trials 2
Nasopharyngitis: Frequently observed during long-term treatment 2
Dizziness: Reported in clinical trials 4
Upper respiratory tract infections and UTIs: Noted during extended treatment periods 4
Serious Side Effects and Warnings
While serious adverse events are uncommon, the FDA labeling for orexin receptor antagonists (the drug class including lemborexant) warns of several potential risks similar to those seen with suvorexant 1:
- Cognitive and behavioral changes: Including amnesia, anxiety, hallucinations, and other neuropsychiatric symptoms
- Complex sleep behaviors: Such as sleep-driving and other activities while not fully awake
- Worsening depression: Including suicidal thinking in individuals with pre-existing depression
- Sleep paralysis and hypnagogic/hypnopompic hallucinations: Experiences of being unable to move or vivid hallucinations when falling asleep or waking
Safety Profile Compared to Other Sleep Medications
Importantly, lemborexant demonstrates a favorable safety profile regarding next-day residual effects. Unlike older sleep medications, lemborexant does not substantially impair:
- Next-morning postural stability 3
- Cognitive performance (minimal impact on attention measures) 3
- Driving ability (no significant impairment versus placebo) 3
- Morning alertness (actually shows improvement versus placebo) 5, 3
Long-Term Safety
In 12-month clinical trials, lemborexant maintained its safety profile with 2:
- Most adverse events remaining mild to moderate in severity
- No evidence of rebound insomnia upon discontinuation
- No withdrawal symptoms after treatment cessation
- Sustained efficacy without tolerance development
Dose-Dependent Considerations
The 5 mg dose appears to offer a better risk-benefit ratio for most patients, particularly those at risk for excessive daytime somnolence 6. While both 5 mg and 10 mg doses are effective, the differences in efficacy are modest, but somnolence risk increases with the higher dose 6, 4.
Special Populations
- Older adults (≥65 years): Lemborexant is well-tolerated in this population with similar adverse event profiles to younger adults 5
- Patients with depression/anxiety: No new safety signals emerged in patients taking medications for depression or anxiety symptoms 7
- Patients with mild obstructive sleep apnea: Lemborexant can be safely used without worsening respiratory parameters 8
Critical Drug Interaction
Avoid concomitant use of lemborexant with moderate or strong CYP3A4 inhibitors like fluconazole, as this increases lemborexant exposure approximately 4-fold, significantly raising the risk of somnolence and other adverse effects 9.
Clinical Bottom Line
Treatment-emergent adverse events occur more frequently with lemborexant than placebo (statistically significant increase) 6, but the absolute rates remain low, discontinuation due to adverse events is rare, and the drug lacks the concerning next-day impairment seen with older hypnotics. Start with 5 mg to minimize somnolence risk while maintaining therapeutic benefit.